23 completed, 3 recruiting, 2 terminated, 1 withdrawn. 29 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Completed 23, Recruiting 3, Terminated 2, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Recruiting 2 |
Follow Olfactory Nerve Diseases: new trials by email Literature Review of Olfactory Nerve Diseases trials Research Report on Olfactory Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors docetaxel, vandetanib, proteomic profiling - Breast Cancer, Head and Neck Cancer | Phase 1 | Withdrawn | SWOG Cancer Research Network | 2008-09-01 | 2017-04-24 | |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer HPPH, photodynamic therapy, conventional surgery - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Roswell Park Cancer Institute | 15 | 2006-10-19 | 2022-07-25 |
| Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Taxotere (Docetaxel), Alimta (Pemetrexed) - Breast Cancer, Esophageal Cancer | Phase 1 | Completed | University of Arizona | 33 | 2005-09-01 | 2015-12-03 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| NGR-TNF in Treating Patients With Advanced Solid Tumors CNGRC peptide-TNF alpha conjugate - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 70 | 2004-09-01 | 2012-09-24 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-07-01 | 2013-04-10 |
| Thalidomide and Docetaxel in Treating Patients With Advanced Cancer docetaxel, thalidomide - Cancer | Phase 1 | Completed | Case Comprehensive Cancer Center | 26 | 2002-07-01 | 2010-06-11 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction erlotinib hydrochloride, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 2001-12-01 | 2013-01-16 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2001-12-01 | 2013-09-30 |
| Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin silicon phthalocyanine 4 - Breast Cancer, Head and Neck Cancer | Phase 1 | Terminated | Case Comprehensive Cancer Center | 3 | 2001-08-01 | 2011-08-24 |
| Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor capecitabine, carboplatin, epirubicin hydrochloride - Esophageal Cancer, Extrahepatic Bile Duct Cancer | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 2001-07-01 | 2012-03-08 | |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer vorinostat - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2001-07-01 | 2013-05-30 | |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer hydroxyurea, fluorouracil, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2001-07-01 | 2013-02-07 |
| MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma entinostat - Cancer | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 75 | 2001-03-01 | 2012-03-15 |
Showing 20 of 29. Sign in to see all of them.
Esthesioneuroblastoma, Olfactory (29) · Squamous Cell Carcinoma of Head and Neck (23) · Salivary Gland Neoplasms (21) · Carcinoma, Non-Small-Cell Lung (17) · Breast Neoplasms (15) · Head and Neck Neoplasms (14) · Colonic Neoplasms (12) · Carcinoma, Ovarian Epithelial (11) · Esophageal Neoplasms (11) · Carcinoma, Renal Cell (10) · Prostatic Neoplasms (10) · Stomach Neoplasms (10) · Breast Neoplasms, Male (9) · Pancreatic Neoplasms (9) · Lung Neoplasms (8)
Cranial Nerve Diseases (29) · Neoplasms by Histologic Type (29) · Neoplasms by Site (29) · Neoplasms, Germ Cell and Embryonal (29) · Neoplasms, Glandular and Epithelial (29) · Neoplasms, Nerve Tissue (29) · Neoplasms, Neuroepithelial (29) · Nervous System Diseases (29) · Neuroectodermal Tumors (29) · Carcinoma (28) · Neuroblastoma (27) · Neuroectodermal Tumors, Primitive (26) · Neuroectodermal Tumors, Primitive, Peripheral (26) · Neoplasms (24)
Docetaxel (6) · Cetuximab (3) · Erlotinib Hydrochloride (3) · Bevacizumab (2) · Capecitabine (2) · Cisplatin (2) · Filgrastim (2) · 1-phenyl-3,3-dimethyltriazene (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (1) · 7-hydroxystaurosporine (1) · Carboplatin (1) · Congresses as Topic (1) · E6 protein, Human papillomavirus type 16 (1) · Epirubicin (1)
National Cancer Institute (NCI) (8) · Case Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · National Institutes of Health Clinical Center (CC) (2) · University of Arizona (2) · City of Hope Medical Center (1) · Dartmouth-Hitchcock Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fox Chase Cancer Center (1) · Fundación de investigación HM (1) · NCIC Clinical Trials Group (1) · NYU Langone Health (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · Sanjiv Sam Gambhir (1)
United States (25) · Canada (1) · Germany (1) · Netherlands (1) · Spain (1)
Scot C. Remick, MD (3) · Alain Mita (1) · Antonius Miller (1) · Barbara Burtness (1) · Barry L. Gause, MD (1) · Brian P. Monahan, MD, FACP (1) · Charles Hsu, MD (1) · Cornelis J. A. Punt, MD, PhD (1) · David Solit (1) · Eva Szabo, MD (1) · Everett Vokes (1) · Franco M. Muggia, MD (1) · Frank I Lin, M.D. (1) · Hal W. Hirte, MD, FRCP(C) (1) · Hassan Arshad (1)
PMID 15033677, PMID 18470481, PMID 20145168, PMID 20407240, PMID 23868427, PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872
P30CA043703 (3), U01CA062502 (2), P30CA016087 (1), P30CA023074 (1), P30CA023108 (1), P30CA033572 (1), P30CA044579 (1), P30CA054174 (1), P30CA068485 (1), U01CA062505 (1), U01CA069853 (1), U01CA069856 (1), U10CA031946 (1)